Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from USFDA for Niacin Extended-Release Tablets USP
Details : Niacin is indicated to reduce elevated total cholesterol (TC), LDL-C, Apo B and TG, also to increase HDL-C in patients with primary hyperlipidaemia and mixed dyslipidaemia.
Product Name : Niaspan-Generic
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 02, 2025
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial
Details : This trial is being conducted to evaluate the safety and tolerability of ATG-019 monotherapy or ATG-019 combined with niacin ER, for the treatment of advanced solid tumors or non-Hodgkin's lymphoma.
Product Name : ATG-019
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2020
Reset All
